Moderna Inc. (MRNA) – Get a report
Stocks jumped in trade before market release on Wednesday after the drug maker reported uniformly positive data from an early trial of its experimental coronavirus vaccine.Moderna said the phase 1 trial of MRNA-1273, its proposed coronavirus vaccine candidate, induced antibody reactions in the 45 participating patients, with no serious side effects, after two injections spanning a period four weeks. The results open the door to a larger study of some 30,000 patients, scheduled for July 27, and follow on from the positive results of vaccine studies reported earlier this week by drug maker Pfizer Inc. (PFE) – Get a report
The director of the National Institute of Allergies and Infectious Diseases, Dr. Anthony Fauci, said that the data seemed “really good” and underline the fact that the patients suffered only slight side effects from the injection , such as headache, fever and fatigue.”These positive phase 1 data are encouraging and represent an important advance in the clinical development of mRNA-1273, our vaccine candidate against COVID-19, and we thank the NIH for its continued collaboration,” said CEO Stephane Bancel . “The Moderna team continues to focus on starting our phase 3 study this month and, if successful, on filing a BLA. “
“We are committed to advancing the clinical development of mRNA-1273 as quickly and safely as possible while investing to expand manufacturing so that we can help respond to this global health emergency,” he said. she adds.
Moderna shares rose 14% in pre-market trading to indicate an opening price of $ 85.50 per share, a move that would take the cumulative share gain to an astonishing 350%.
Earlier this week, Pfizer obtained “accelerated” approval from the United States Food & Drug Administration for two of its candidate coronavirus vaccines. the drug manufacturer is developing in collaboration with BioNTech BNTX in Germany, following preliminary data from phase 1 and phase 2 studies earlier this month.
Pfizer previously reported preliminary results from its study on the coronavirus vaccine which it says triggered a “strong immune response” in human trials, and unveiled plans to test the most promising of its four candidate vaccines on up to 30,000 participants in trials planned for states and Europe.
No serious side effects were reported in the study, said Pfizer, which included two-dose tests of BNT1162b1 on 24 healthy volunteer patients, but those treated showed higher levels of COVID-19 antibodies compared to those infected with the disease.